IPP Bureau
Experts call for easing access to 2mg and 4mg nicotine replacement therapies
By IPP Bureau - May 07, 2026
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
Free HLA typing for children with thalassaemia launched in India
By IPP Bureau - May 07, 2026
The initiative by DKMS Foundation India is for below 12 years children suffering from transfusion-dependent thalassemia
China poised to launch world’s first CAR-T therapy for gastric cancer
By IPP Bureau - May 07, 2026
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Neurobion introduces nerve pain relief cream
By IPP Bureau - May 07, 2026
The formulation contains 0.075% Capsaicin, a clinically proven ingredient along with menthol, camphor and eucalyptus oil
GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD
By IPP Bureau - May 07, 2026
This is an exciting and meaningful milestone for GRIN Therapeutics
Merck completes $5.8 billion acquisition of Terns Pharma
By IPP Bureau - May 07, 2026
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum
By IPP Bureau - May 07, 2026
The standout story remains Wegovy, particularly its new oral formulation
Eli Lilly unveils $4.5 bn Indiana expansion
By IPP Bureau - May 07, 2026
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints
By IPP Bureau - May 06, 2026
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Ajanta Pharma Q4 FY26 revenue surges 21% to Rs. 1,422 Crore; PAT climbs 18%
By IPP Bureau - May 06, 2026
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal
By IPP Bureau - May 06, 2026
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%
By IPP Bureau - May 06, 2026
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility
By IPP Bureau - May 06, 2026
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
